Stay updated on Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page
- Check2 days agoChange DetectedNew sections for user guidance (How to Read a Study Record, Common Questions, How to Join a Study) and a No longer looking for participants notice were added, while the Intervention/Treatment header was standardized. The sponsor designation was updated to Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest and the page revision shows v3.6.0 (replacing v3.5.5).SummaryDifference0.5%

- Check9 days agoChange DetectedThe revision label on the page was updated from v3.5.4 to v3.5.5, signaling a new revision of the page content; this appears to be an internal version update.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision: v3.5.4 is now shown on the page, replacing the previous v3.5.3. This reflects an updated revision of the study record.SummaryDifference0.1%

- Check51 days agoChange DetectedThis updates the ClinicalTrials.gov page’s revision/version indicator from v3.5.2 to v3.5.3, reflecting a platform release rather than a change to the underlying study information.SummaryDifference0.1%

- Check58 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check80 days agoChange DetectedResults posted with expanded outcome measures (ORR, TTR, Recurrence Free Survival, OS) and biomarker analyses, plus related study documents.SummaryDifference2%

Stay in the know with updates to Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.